血脂康联合瑞舒伐他汀对动脉粥样硬化性心血管疾病患者调脂疗效的研究

Study on the Effect of Xuezhikang Combined with Rosuvastatin on Lipid Regulation in Patients with Atherosclerotic Cardiovascular Disease

摘要: 目的：评估血脂康联合瑞舒伐他汀对动脉粥样硬化性心血管疾病(ASCVD)患者调脂程度、达标率及安全性的影响。方法：将符合纳排标准的ASCVD患者按随机数字表法分为血脂康组(A组)、瑞舒伐他汀组(B组)、联合用药组(C组)。在治疗前后检测血浆TC、TG、HDL-C、LDL-C，监测副反应，比较治疗前后颈动脉内膜中层厚度(IMT)、斑块积分(Crouse积分)、斑块稳定性、LDL-C达标率变化。结果：3组除HDL-C升高外，TC、TG、LDL-C均下降，C组、B组、A组降LDL-C效果依次递减(P_A:B < 0.001, P_A:C < 0.001, P_B:C < 0.001)。治疗后各组IMT、Crouse积分、斑块稳定性均较前改善，各治疗组治疗后LDL-C达标率，C组、B组、A组依次下降(P_A:B < 0.001, P_A:C < 0.001, P_B:C = 0.002)，各治疗组安全可靠( χ² = 0.448, p = 0.799, p > 0.05)。结论：血脂康联合瑞舒伐他汀可明显降低ASCVD患者血浆TC、TG、LDL-C，提高血浆LDL-C达标率，兼具安全性的同时稳定斑块。

Abstract: OBJECTIVE: To evaluate the effect of Xuezhikang combined with rosuvastatin on the degree, success rate and safety of lipid regulation in patients with atherosclerotic cardiovascular disease (ASCVD). MEATHODS: According to the random number table method, patients with ASCVD who meet the standard of natriuretic discharge were randomly divided into Xuezhikang group (group A), rosuvastatin group (group B) and combination group (Group C). Plasma TC, TG, HDL-C and LDL-C were measured before and after treatment, even the side effects were monitored. Compared carotid intima-media thickness (IMT), plaque score (Crouse score), plaque stability before and after treatment and the LDL-C success rate. RESULTS: Except for HDL-C increase, TC, TG and LDL-C all decreased in the 3 groups and the effects of reducing LDL-C ingroup C, group B, and group A decreased successively (P_A:B < 0.001, P_A:C < 0.001, P_B:C < 0.001). After treatment the IMT, Crouse score and plaque stability of each group were improved. The success rate of reaching the standard of LDL-C in the group C, group B and group A decreased in turn (P_A:B < 0.001, P_A:C < 0.001, P_B:C = 0.002) and all treatment groups were safe and reliable (χ² = 0.448, p = 0.799, p > 0.05). CONCLUSION: Xuezhikang combined with rosuvastatin can significantly reduce plasma TC, TG and LDL-C in patients with ASCVD, improve the success rate of LDL-C, and stabilize the plaque with safety.